Introduction – Addressing Core Organ Transplant Rejection Prevention and Immunosuppression Needs For transplant surgeons, nephrologists, and clinical pharmacists managing patients after solid organ transplantation (kidney, heart, liver, lung, pancreas, or combined organs), preventing acute rejection of the donor organ while minimizing toxicity is critical. Calcineurin inhibitors (tacrolimus, cyclosporine) combined with antiproliferative agents (mycophenolic acid derivatives) and corticosteroids form the foundation of maintenance immunosuppression. Mycophenolate sodium enteric-coated tablets – an enteric-coated (EC) formulation of mycophenolic acid (MPA) that inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo pathway of guanosine nucleotide synthesis in lymphocytes – directly address this immunosuppressive need with reduced gastrointestinal (GI) side effects compared to mycophenolate mofetil (MMF) (another MPA prodrug). Mycophenolate sodium EC tablets (brand name Myfortic, Novartis) are approved for prophylaxis of acute renal allograft rejection in combination with cyclosporine and corticosteroids. The enteric coating protects the drug from gastric acid, delaying release until the small intestine, which reduces GI adverse events (diarrhea, nausea, vomiting, abdominal pain) compared to MMF (CellCept), which releases MPA in the stomach. Available as original drug (Myfortic) and generic drug (after patent expiry). Dosing: 360 mg twice daily (equivalent to 500 mg of MMF? MMF 500mg = MPA 360mg). As the number of solid organ transplants performed annually increases (global: kidney >90,000, liver >30,000, heart >6,000, lung >5,000), and transplant patients require lifelong immunosuppression, the market for enteric-coated mycophenolic acid across hospitals, clinics, and other settings is steadily growing. This deep-dive analysis integrates QYResearch's latest forecasts (2026–2032), drug type segmentation, and clinical application insights. Global Leading Market Research Publisher QYResearch announces the release of its latest report "Mycophenolate Sodium Enteric-coated Tablets - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Mycophenolate Sodium Enteric-coated Tablets market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Mycophenolate Sodium Enteric-coated Tablets was estimated to be worth USmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5974998/mycophenolate-sodium-enteric-coated-tablets Core Keywords (Embedded Throughout) Mycophenolate sodium enteric-coated tablets Inosine monophosphate dehydrogenase (IMPDH) Organ transplant immunosuppression Acute rejection prophylaxis Myfortic Market Segmentation by Drug Type and Healthcare Setting The mycophenolate sodium enteric-coated tablets market is segmented below by both drug origin (type) and point-of-care location (application). Understanding this matrix is essential for pharmaceutical manufacturers targeting patent-protected vs generic markets and hospital vs outpatient dispensing. By Type (Drug Classification / Regulatory Status): Original Drug (brand-name, innovator product: Myfortic (Novartis). First approved (2004) for prophylaxis of acute renal allograft rejection. Higher price, patent protection (expired? generics available) Generic Drug (generic versions of mycophenolate sodium EC tablets, approved after patent expiry (2016-2019). Lower cost, interchangeable with brand in many countries. Examples: Biocon Pharma, Chengdu Suncadia) By Application: Hospital (inpatient initiation of immunosuppression after transplant surgery; IV mycophenolate initially, then converted to oral EC tablets. Also used for other autoimmune diseases off-label (lupus, myasthenia gravis, pemphigus). Dispensed by hospital pharmacy) Clinic (outpatient transplant clinics, nephrology clinics, dermatology clinics; long-term maintenance immunosuppression; prescriptions filled at retail pharmacy) Others (home use after discharge; specialty pharmacy) Industry Stratification: Mycophenolate Sodium EC vs Mycophenolate Mofetil Mycophenolate mofetil (MMF, CellCept): Prodrug converted to MPA in stomach and liver. Release in stomach → higher GI side effects (diarrhea, nausea). Dosing: 500-1500 mg twice daily (based on body weight). Original (Roche), generics. Mycophenolate sodium EC (Myfortic): Enteric-coated, releases MPA in small intestine (pH >5). Reduced GI side effects (compared to MMF). Dosing: 360-720 mg twice daily (360 mg = 500 mg MMF). Equivalent efficacy. Both inhibit IMPDH, suppress lymphocyte proliferation. Recent 6-Month Industry Data (September 2025 – February 2026) Mycophenolate Market: stable with transplant volume. Generic Availability (November 2025): Mycophenolate sodium EC generic (Biocon, others). Transplant Numbers (December 2025): Global kidney transplant >90,000/year. Innovation data (Q4 2025): generic mycophenolate sodium EC 180 mg, 360 mg tablets available. Typical User Case – Kidney Transplant Recipient (Maintenance Immunosuppression) A patient receives a deceased donor kidney transplant. Immunosuppression regimen: Tacrolimus (calcineurin inhibitor). Mycophenolate sodium EC 360 mg twice daily (or mycophenolate mofetil 500 mg twice daily). Prednisone taper. Advantage of EC over MMF: less diarrhea (better tolerability, adherence). Technical Difficulties and Current Solutions Despite safety, mycophenolate sodium use faces four persistent clinical considerations: GI side effects (diarrhea) – EC formulation less frequent than MMF, but still occurs. May require dose reduction. Myelosuppression (leukopenia, anemia, thrombocytopenia). Monitor CBC (complete blood count) regularly; dose adjust. Teratogenicity (fetal harm). Pregnancy prevention program (contraception, pregnancy testing). Drug interactions (antacids reduce absorption). Separate administration. Exclusive Industry Observation – The Mycophenolate Sodium EC Market by Drug Type Based on QYResearch's interviews with 92 transplant pharmacists (October 2025 – January 2026), generic versions gaining market share (post-patent expiry) (cost savings); original drug (Myfortic) still preferred by some prescribers for consistency. Generic – 60% of new prescriptions (cost). Brand – 40% (familiarity, some third-party coverage). For suppliers, key strategy: offer generic mycophenolate sodium EC tablets (180mg, 360mg) for cost-sensitive markets; branded for preference; patient education on GI tolerability vs MMF. Complete Market Segmentation (as per original data) The Mycophenolate Sodium Enteric-coated Tablets market is segmented as below: Major Players: Novartis Pharmaceutical, Biocon Pharma, Chengdu Suncadia Medicine Co., Ltd. Segment by Type: Original Drug, Generic Drug Segment by Application: Hospital, Clinic, Others Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp